Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infection.
[1] This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School.
[2] The project was then licensed to Merck & Co., Inc. for further development and commercialization.
[3] A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.
[4] This monoclonal antibody–related article is a stub.